Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cartesian Therapeutics, Inc. - Common Stock
(NQ:
RNAC
)
17.91
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cartesian Therapeutics, Inc. - Common Stock
Argenx Stock Surges As Amgen Struggles To Take On 'The King' In Autoimmune Diseases
September 25, 2024
Amgen tested its drug, Uplizna, in generalized myasthenia gravis, a market where Argenx's Vyvgart leads.
Via
Investor's Business Daily
RNAC Stock Earnings: Cartesian Therapeutics Beats EPS, Beats Revenue for Q2 2024
August 08, 2024
RNAC stock results show that Cartesian Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Why NIO Shares Are Trading Lower By Over 8%? Here Are Other Stocks Moving In Friday's Mid-Day Session
July 05, 2024
Shares of NIO Inc. (NYSE:NIO) fell sharply during Friday's session after the company disclosed that Steven Wei Feng has resigned as the Chief Financial Officer for personal and family
Via
Benzinga
Cartesian Therapeutics Plummets On 'Watershed Moment' For CAR-T Drugs
July 02, 2024
The company is the first to test a CAR-T drug against a placebo in patients with an autoimmune disease.
Via
Investor's Business Daily
Cartesian's Autoimmune Disorder Candidate Hits Primary Goal In Mid-Stage Study, Announces Equity Raise Of $130M
July 02, 2024
Cartesian Therapeutics reported Phase 2b trial results for Descartes-08 in generalized myasthenia gravis, showing significant improvements in MG Composite scores with a favorable safety profile. The...
Via
Benzinga
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q1 2024
May 08, 2024
RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Cartesian Therapeutics Announces New Employment Inducement Grants
May 06, 2024
From
Cartesian Therapeutics, Inc.
Via
Business Wire
Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 23, 2024
Via
Benzinga
HealthStream Reports Upbeat Results, Joins Spotify, Ryder System And Other Big Stocks Moving Higher On Tuesday
April 23, 2024
Via
Benzinga
Cartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
April 22, 2024
From
Cartesian Therapeutics, Inc.
Via
Business Wire
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
April 16, 2024
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed fourth-quarter financial results and issued FY25 revenue guidance below estimates.
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
April 15, 2024
Via
Benzinga
Cartesian Therapeutics' Rare Disease Candidate Shows Long Lasting Benefit Over Argenx's Vyvgart, Analyst Initiates With Buy
April 10, 2024
Cartesian Therapeutics' autoimmune disease treatment with re-dosable mRNA CAR-Ts. Learn about Descartes-08, a promising anti-BCMA CAR-T therapy offering deeper, longer-lasting efficacy than current...
Via
Benzinga
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Cartesian Therapeutics, Inc.
Via
Business Wire
Cartesian Therapeutics Announces New Employment Inducement Grants
April 04, 2024
From
Cartesian Therapeutics
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
March 28, 2024
Via
Benzinga
LivePerson And 2 Other Stocks Under $2 Insiders Are Buying
March 19, 2024
The Dow Jones index closed higher by around 75 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
RNAC Stock Earnings: Cartesian Therapeutics Misses EPS, Beats Revenue for Q4 2023
March 07, 2024
RNAC stock results show that Cartesian Therapeutics missed analyst estimates for earnings per share but beat on revenue for the fourth quarter of 2023.
Via
InvestorPlace
SolarEdge Layoffs 2024: What to Know About the Latest SEDG Job Cuts
January 22, 2024
SolarEdge layoffs are coming for 16% of the company's workers as it prepares to reduce its total headcount by 900 employees.
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Why Is Cartesian Therapeutics (RNAC) Stock Down 5% Today?
January 22, 2024
Cartesian Therapeutics stock is falling on Monday as investors react to a delisting notice for RNAC shares due to its low trading price.
Via
InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
January 22, 2024
We're starting the trading week with a breakdown of the biggest pre-market stock movers worth knowing about on Monday!
Via
InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 10, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
December 01, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.